Floatz Rating
B61/100
Confidence
Indicative
Sponsor
University of Miami
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07278362CT.gov Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance | — | Not Yet Recruiting | — | — | — |
NCT06305598CT.gov Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06039371CT.gov Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study | — | Recruiting | — | — | — |
NCT06059118CT.gov Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04558866CT.gov Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial) | — | Active Not Recruiting | — | — | — |
NCT04424654CT.gov Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy | — | Completed | — | — | — |
NCT03716739CT.gov Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency | — | Completed | — | — | — |
NCT03554317CT.gov COMbination of Bipolar Androgen Therapy and Nivolumab | — | Completed | — | — | — |
NCT02995330CT.gov Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT02090114CT.gov RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT01750398CT.gov Bipolar Androgen-based Therapy for Prostate Cancer (BAT) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Testosterone Cipionate (this asset) | University of Miami | Approved | B · 61 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Testosterone Cipionate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P2 | BB · 64 |
| Hypogonadism, Male | — | P4 | B · 62 |
| Substance-Related Disorder | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Testosterone Cipionate in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/testosterone-cipionate-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →